Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 5, Pages 703-710Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.40
Keywords
Alzheimer's disease; amyloid peptide; GSK-3; lithium; tau
Categories
Funding
- Spanish Ministry of Health [SAF 2006-02424]
- Ciberned [CB06/05/0035]
- Noscira [2008/285]
- Comunidad de Madrid [SAL/0202/2006]
- Fundacion Marcelino Botin
- Fundacion CIEN [PI008/09]
- Fundacian Ramon Areces
- DGCYT [SAF2009-12249-C02-01, CDTI-CENIT-INGENIO 2010]
- Fundacion Areces [EU-FP7-2009-CT22288Z]
Ask authors/readers for more resources
Glycogen synthase kinase (GSK)-3 has been proposed as the link between the two histopathological hallmarks of Alzheimer's disease, the extracellular senile plaques composed of beta-amyloid and the intracellular neurofibrillary tangles formed from hyperphosphorylated tau. Thus, GSK-3 is one of the main tau kinases and it modifies several sites of the tau protein present in neurofibrillary tangles. Furthermore, GSK-3 is able to modulate the generation of amyloid-beta, as well as to respond to this peptide. In several transgenic models, overexpression of GSK-3 has been associated with neuronal death, tau hyperphosphorylation and a decline in cognitive performance. Lithium, a widely used drug for affective disorders, inhibits GSK-3 at therapeutically relevant concentrations and it has been demonstrated that this is able to prevent tau phosphorylation. In the present review, we summarize all these data and discuss the potential of GSK-3 inhibitors for Alzheimer's disease therapy, as well as some of their potential problems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available